6 research outputs found
Efficacy of two dosages of dexamethasone administered by submucosal injection on postoperative sequelae after third molar surgery: A retrospective study
No full textABSTRACT: Purpose: A retrospective clinical study was performed to compare the post-operative sequelae of the submucosal administration of two different low dosages of dexamethasone, after the surgical extraction of lower third molars. Methods: Data regarding edema, trismus, pain and analgesic consumption were collected from 150 subjects, selecting three equal groups (n= 50): a control group with no administered dexamethasone (G1); submucosal injection of dexamethasone 2 mg/0.5 ml (G2) and submucosal injection of dexamethasone 4 mg/1 ml (G3). Collected data were evaluated at three different time points: T0 before surgery, T1 on the third day after surgery and T2 on the 7th day after surgery. Patients’ gender and age were also considered for statistical purposes. Results: The effects on facial swelling reduction were statistically significant in G2 at T1 in the male subgroup. With trismus, the differences between the time points considered were statistically significant in G2 in the subgroup of subjects younger than 25 years old. Differences in analgesics taken were statistically significant when G1 and G2 were compared at T1. (Am J Dent 2022;35:233-237)
Gingival overgrowth caused by Olmesartan Medoxomil: Observational study
No full textObjective: Olmesartan Medoxomil is a type 1 receptor antagonist an antagonist of type 1 receptor (AT1) of angiotensin II (A-II) that inhibits numerous actions of A-II in the renin-angiotensin-aldosterone system (RAAS). A-II is a significant and multifunctional peptide involved in the pathophysiology of blood hypertension and for this reason it represents the main target in several classes of drugs used to treat and control arterial hypertension, such as angiotensin converting enzyme inhibitors (ACE-i), angiotensin receptor blockers (ARB) and renin direct inhibitors. The aim of the study is to evaluate whether the two drugs that have as an active principle Olmesartan Medoxomil, with and without the diuretic hydrochlorothiazide, are able to determine gingival overgrowth. Study Design: 108 subjects were examined and divided into three groups: G1, subjects treated with Olmesartan Medoxomil and hydrochlorothiazide (n=60); G2, subjects received only Olmesartan Medoxomil (n=24); G3, control group without pharmacological therapies (n=24). The plaque index (IP) and the gingival overgrowth index (OI) were recorded, considering the vertical and horizontal components. Results: Vertical overgrowth averaged between 0.17 ± 0.15 (G3) and 0.34 ± 0.26 (G2) showing statistically significant differences (p <0.05) compared to the other groups. Horizontal overgrowth ranged from 0.18 ± 0.26 (G3) to 0.49 ± 0.35 (G2) showing statistically significant differences (p <0.05). Conclusions: antihypertensive agents as Olmesartan Medoxomil may result in mild gingival overgrowth in the upper and lower frontal dental elements not related to other etiological factors
Hepatic epithelioid hemangioendothelioma (HEH) at MRI using reticuloendothelial system (RES)-specific contrast agent: the "bright-bright sign" rather than the "bright-dark sign"
No full textİleri Evre Tiroid Medüller Karsinomda Vandetanib'in Etkinliği ve Güvenirliği
No full textGİRİŞMedüllertiroid karsinomu(MTK), tiroid parafollüküler hücrelerden kaynaklanannöroendokrin tümördür. İleri evre medüller tiroid karsinomunun sistemiktedavisinde tirozin kinaz inhibitörlerinin(TKI) etkinliği gösterilmiştir. ADDIN EN.CITE<EndNote><Cite><Author>Ceolin</Author><Year>2019</Year><RecNum>147</RecNum><DisplayText>[1]</DisplayText><record><rec-number>147</rec-number><foreign-keys><keyapp="EN" db-id="zre2stpsufsvw5edfsp5x9rrdaavwvwvxrrf"timestamp="1647178785">147</key></foreign-keys><ref-typename="Journal Article">17</ref-type><contributors><authors><author>Ceolin,Lucieli</author><author>da Silveira Duval, MartaAmaro</author><author>Benini, AntônioFelippe</author><author>Ferreira, CarlaVaz</author><author>Maia, AnaLuiza</author></authors></contributors><titles><title>Medullarythyroid carcinoma beyond surgery: advances, challenges, andperspectives</title><secondary-title>Endocrine-relatedcancer</secondary-title></titles><periodical><full-title>Endocrine-relatedcancer</full-title></periodical><pages>R499-R518</pages><volume>26</volume><number>9</number><dates><year>2019</year></dates><isbn>1351-0088</isbn><urls></urls></record></Cite></EndNote>[1]Vandetanib, oral multihedef kinaz inhibitörüdür. Yapılan faz II/IIIçalışmalarda etkinliği ve güvenliği gösterilmiştir. ADDIN EN.CITE<EndNote><Cite><Author>Wells Jr</Author><Year>2012</Year><RecNum>129</RecNum><DisplayText>[2]</DisplayText><record><rec-number>129</rec-number><foreign-keys><keyapp="EN" db-id="zre2stpsufsvw5edfsp5x9rrdaavwvwvxrrf"timestamp="1642441403">129</key></foreign-keys><ref-typename="Journal Article">17</ref-type><contributors><authors><author>WellsJr, Samuel A</author><author>Robinson, BruceG</author><author>Gagel, RobertF</author><author>Dralle,Henning</author><author>Fagin, James A</author><author>Santoro,Massimo</author><author>Baudin, Eric</author><author>Elisei,Rossella</author><author>Jarzab,Barbara</author><author>Vasselli, JamesR</author></authors></contributors><titles><title>Vandetanibin patients with locally advanced or metastatic medullary thyroid cancer: arandomized, double-blind phase IIItrial</title><secondary-title>Journal of clinicaloncology</secondary-title></titles><periodical><full-title>Journalof clinicaloncology</full-title></periodical><pages>134</pages><volume>30</volume><number>2</number><dates><year>2012</year></dates><urls></urls></record></Cite></EndNote>[2]Biz de kliniğimizde MTK tanılı hastalarda, vandetanibin etkinliğini vegüvenliğini araştırdık.METODOcak2016-Aralık 2021 tarihleri arası Dokuz Eylül Üniveristesi Tıbbi Onkolojikliniğinde MTK tanısı ile vandetanib alan 14 hastaın verileri retrospektifolarak tarandı. Analizler IBM SPSS Stastistics 24.0 kullanılarak yapıldı. P< 0.05 değeri anlamlı olarak kabuledildi. Tanımlayıcı istatistiki analizler yapıldı. Sağkalım analizleri içinKaplan-Meier, değişkenleri hesaplamak için cox-regresyon modeli kullanıldı. Klinik yanıt oranları RECİST 1.1' e göre,yan etkilerinin derecesi Common Terminology Criteria for Adverse Events (CTCAE)Version 4.0'e göre sınıflandırıldı.BULGULARToplam14 hastanın 4’ünde veriler yetersiz olduğu için çalışmadan çıkarıldı. 10hastanın 4(%40)’ı kadındı. Hastalığa bağlı ölüm görülmedi. Ortalama takipsüresi 36.7 aydı( 14.5 ay-55 ay). Ortanca genel sağkalım 22.4 ay, progresyonsuzsağkalım 14.8 aydı (p=0.001). Ortalama yanıt süresi 6.8 aydı. Yanıtoranları,kalsitoinin ve CEA değişimi ile korele idi. Hipetansiyon, cilttoksistesi,QT uzaması, bulantı, kusma en sık görülen yan etkilerdi. 4 hasta yanetkiler nedeni ile tedavi kesildi(2 hasta QT uzaması, 2 hasta hipertansiyon).SONUÇBulgularımız,birinci/ikinci basamak vandetanib alan önemli sayıda hastanın uzun süreliklinik fayda sağlayabileceğini göstermektedir. Ancak yan etkiler nedeni iletedaviyi bırakma oranı yüksektir. ADDIN EN.CITE<EndNote><Cite><Author>Resteghini</Author><Year>2017</Year><RecNum>149</RecNum><DisplayText>[3]</DisplayText><record><rec-number>149</rec-number><foreign-keys><keyapp="EN" db-id="zre2stpsufsvw5edfsp5x9rrdaavwvwvxrrf"timestamp="1647179271">149</key></foreign-keys><ref-typename="JournalArticle">17</ref-type><contributors><authors><author>Resteghini,C</author><author>Cavalieri,S</author><author>Galbiati, D</author><author>Granata,R</author><author>Alfieri, S</author><author>Bergamini,C</author><author>Bossi, P</author><author>Licitra,L</author><author>Locati,LD</author></authors></contributors><titles><title>Managementof tyrosine kinase inhibitors (TKI) side effects in differentiated andmedullary thyroid cancer patients</title><secondary-title>Bestpractice &amp; research Clinical endocrinology &amp;metabolism</secondary-title></titles><periodical><full-title>Bestpractice &amp; research Clinical endocrinology &amp;metabolism</full-title></periodical><pages>349-361</pages><volume>31</volume><number>3</number><dates><year>2017</year></dates><isbn>1521-690X</isbn><urls></urls></record></Cite></EndNote>[3]Hasta sayısının az olması, çalışmanın retrospektif olması nedeni ile daha fazlaçalışmaya ihtiyaç vardır.</p
Reductions in cardiovascular, cerebrovascular, and respiratory mortality following the national Irish smoking ban: Interrupted time-series analysis
No full textCopyright @ 2013 Stallings-Smith et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.This article has been made available through the Brunel Open Access Publishing Fund.Background: Previous studies have shown decreases in cardiovascular mortality following the implementation of comprehensive smoking bans. It is not known whether cerebrovascular or respiratory mortality decreases post-ban. On March 29, 2004, the Republic of Ireland became the first country in the world to implement a national workplace smoking ban. The aim of this study was to assess the effect of this policy on all-cause and cause-specific, non-trauma mortality. Methods: A time-series epidemiologic assessment was conducted, utilizing Poisson regression to examine weekly age and gender-standardized rates for 215,878 non-trauma deaths in the Irish population, ages ≥35 years. The study period was from January 1, 2000, to December 31, 2007, with a post-ban follow-up of 3.75 years. All models were adjusted for time trend, season, influenza, and smoking prevalence. Results: Following ban implementation, an immediate 13% decrease in all-cause mortality (RR: 0.87; 95% CI: 0.76-0.99), a 26% reduction in ischemic heart disease (IHD) (RR: 0.74; 95% CI: 0.63-0.88), a 32% reduction in stroke (RR: 0.68; 95% CI: 0.54-0.85), and a 38% reduction in chronic obstructive pulmonary disease (COPD) (RR: 0.62; 95% CI: 0.46-0.83) mortality was observed. Post-ban reductions in IHD, stroke, and COPD mortalities were seen in ages ≥65 years, but not in ages 35-64 years. COPD mortality reductions were found only in females (RR: 0.47; 95% CI: 0.32-0.70). Post-ban annual trend reductions were not detected for any smoking-related causes of death. Unadjusted estimates indicate that 3,726 (95% CI: 2,305-4,629) smoking-related deaths were likely prevented post-ban. Mortality decreases were primarily due to reductions in passive smoking. Conclusions: The national Irish smoking ban was associated with immediate reductions in early mortality. Importantly, post-ban risk differences did not change with a longer follow-up period. This study corroborates previous evidence for cardiovascular causes, and is the first to demonstrate reductions in cerebrovascular and respiratory causes
